Natural Adjuvants (PC and G2) Induce Activated Natural Killer Cells with NKG2D Expression and Cytotoxic Properties in Colorectal Cancer
Gastroenterology and Hepatology from Bed to Bench,
Colorectal cancer is one of the most commonly reported cancers. Cell and gene therapies of cancer have received much attention in the past decade. Natural killer (NK) cells are an element of the innate immune system that can recognize and kill cancer cells and provide hope for cancer therapy. One of the current methods in tumor immunotherapy is NK cell therapy. Here, it was proposed that PC and G2 adjuvants can function as NK activator to convert these cells into the cytotoxic natural killer cell for further cytotoxicity effect.
For this purpose, 12 Patients with colorectal cancer were qualified for this study. Peripheral blood mononuclear cell (PBMC) of each patient with two distinctive concentrations ( and 5 Cells/well) was treated with Interleukin2 (IL2), PC, and G2 adjuvant separately. The NK cell's surface marker, including CD16, CD56, and NKG2D, was evaluated by flow cytometry. The cytotoxicity of treated PBMCs as effector cells against NK sensitive cells line (K562) was evaluated with the LDH assay method.
The results showed that the PC and G2 adjuvants could induce cytotoxic NK cells with high expression of NKG2D. Besides, the PC and G2 adjuvants could induce cytotoxic natural killer cells with cytotoxicity against K562 cells.
Finally, it can be stated that the PC and G2 adjuvants could be a candidate to induce cytotoxic killer cell.
- Colorectal cancer, natural killer cells, PC adjuvant, G2 adjuvant, NKG2D, Cytotoxicity
How to Cite
2. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, et al. Human natural killer cells. International Archives of Allergy and Immunology. 2014;164(4):253–64.
3. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-011. Journal of the National Cancer Institute. 1988;80(1):21–9.
4. Dougan M, Dranoff G. Immunotherapy of cancer. In: Innate Immune Regulation and Cancer Immunotherapy. Springer; 2012. p. 391–414.
5. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020 Jan 14;52(1):17-35.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer. 2008;8(4):299–308.
7. Yu Y, Cho H-I, Wang D, Kaosaard K, Anasetti C, Celis E, et al. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. The Journal of Immunology. 2013;190(4):1873–81.
8. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225(4669):1487–9.
9. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren H-G, et al. A new method for in vitro expansion of cytotoxic human CD3− CD56+ natural killer cells. Human immunology. 2001;62(10):1092–8.
10. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer research. 2009;69(9):4010–7.
11. Jäkel CE, Hauser S, Rogenhofer S, Müller SC, Brossart P, Schmidt-Wolf IGH. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clinical and Developmental Immunology. 2012;2012.
12. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert opinion on biological therapy. 2012;12(6):673–84.
13. Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A. NKG2D and its ligands:“one for all, all for one”. Frontiers in immunology. 2018 Mar 12;9:476.
14. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–9.
15. Neamati A, Boskabady MH, Afshari JT, Hazrati SM, Rohani AH. The effect of natural adjuvants on tracheal responsiveness and cell count in lung lavage of sensitized guinea pigs. Respirology. 2009;14(6):877–84.
16. Mohaghegh HS, Khanbaba CR, Mazaheri B, Gharagozlo MJ. A novel and invasive metastatic adenocarcinoma of breast cancer (HAZ-1) in small laboratory mice. In: 14th Iranian congress of Physiology and Pharmacology. 1999. p. 262.
17. Mirsadraee M, Hazrati SM, Khakzad MR, Ghafarzadegan K, Boskabady MH. Preventive Effect of Novel Bacterial Polysaccharide and Animal Splenic Protein as Natural Adjuvants on Animal Model of Asthma. Iranian journal of basic medical sciences. 2012;15(5):1068.
18. Samadder NJ, Jasperson K, Burt RW. Hereditary and common familial colorectal cancer: evidence for colorectal screening. Digestive diseases and sciences. 2015 Mar 1;60(3):734-47.
19. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124(2):544–60.
20. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112(2):594–642.
21. English D, Andersen BR. Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. Journal of immunological methods. 1974;5(3):249–52.
22. Higdon LE, Lee K, Tang Q, Maltzman JS. Virtual Global Transplant Laboratory Standard Operating Procedures for Blood Collection, PBMC Isolation, and Storage. Transplantation Direct. 2016;2(9).
23. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, et al. Thymoglobulin, interferon-g and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129.
24. Herberman R. Mechanisms and pharmacology of NK cell activity. Advances in Immunopharmacology. 2016;3:189–200.
25. Asadirad A, Mahmoud S, Baghaei K, Ghanbarian H. Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155. Life Sciences [Internet]. 2019;219(October 2018):152–62.
26. Chan FK-M, Moriwaki K, De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase activity. Immune Homeostasis: Methods and Protocols. 2013;65–70.
27. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7–30.
28. Neamati A, Boskabady MH, Hazrati SM, Khakzad MR, Moosavi SH. The effect of natural adjuvants (G2, G2F) on lung inflammation of sensitized guinea pigs. Avicenna journal of phytomedicine. 2013;3(4):364.
29. Alvarnas JC, Linn Y-C, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2001;7(4):216–22.
30. Tomchuck SL, Leung WH, Dallas MH. Enhanced cytotoxic function of natural killer and CD3+ CD56+ cells in cord blood after culture. Biology of Blood and Marrow Transplantation. 2015;21(1):39–49.
31. Chelyapov N, Gonzalez R. Natural Killer Cells and Methods for Enhancing Viability, Proliferation and Cytotoxicity of Same Following Cryopreservation. Google Patents; 2015.
32. Hazrati SM, Aghazadeh J, Mohtarami F, Abouzari M, Rashidi A. Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report. Neuroimmunomodulation. 2006;13(4):205–8.
33. Khodadadi A, Abdoli Z, Boroujerdnia MG, Assarehzadegan MA, Ghasemi M, Hazrati SM, Gerdabi ND. The Effect of G2 Adjuvant on Gene Expression and Delivery of NKG2D Receptor on NK Cells in Peripheral Blood. Cancer Biotherapy and Radiopharmaceuticals. 2016 May 1;31(4):119-24.
- Abstract Viewed: 0 times
- pdf Downloaded: 0 times